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Capsule  32 
Blastocoel fluid displays high levels of mosaicism and has low karyotype concordance between 33 
the embryo inner cell mass and trophectoderm, making it unsuitable for diagnostic purposes. 34 
Abstract 35 
Objective: To compare the genomic profiles of blastocoel fluid (BF), inner cell mass (ICM) and 36 
trophectoderm (TE) cells derived from the same blastocyst. 37 
Design: Prospective study. 38 
Setting: Academic and in vitro fertilization units. 39 
Patient(s): Sixteen donated cryopreserved embryos at blastocyst stage. 40 
Intervention(s): BF, TE and ICM cells were retrieved from each blastocyst for chromosome 41 
analysis using next-generation sequencing (NGS).  42 
Main Outcome Measure(s): Aneuploidy screening and assessment of mosaicism in BF, TE and 43 
ICM samples with subsequent comparison of genomic profiles between the three blastocyst 44 
compartments.  45 
Result(s): Out of 16 blastocysts 10 BF samples and 14 TE and ICM samples provided reliable 46 
NGS data for comprehensive chromosome analysis. Only 40.0% of BF-DNA karyotypes were 47 
fully concordant to TE or ICM, compared to 85.7% between TE and ICM. In addition, BF-DNA 48 
was burdened with mosaic aneuploidies and the total number of affected chromosomes in BF 49 
was significantly higher compared to the TE and ICM (P < 0.0001).  50 
Conclusion(s): BF-DNA can be successfully amplified and subjected to NGS, but due to 51 
increased discordance rate between ICM and TE, BF does not adequately represent the status of 52 
the rest of the embryo. To overcome biological and technical challenges, associated with BF 53 
sampling and processing, blastocentesis would require improvement in both laboratory protocols 54 
and aneuploidy calling algorithms. Therefore, TE biopsy remains the most effective way to 55 
predict embryonic karyotype, while the use of BF as a single source of DNA for preimplantation 56 
genetic screening is not yet advised.  57 
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Introduction 65 
Chromosomal aneuploidy in human preimplantation embryos is considered to be a major cause 66 
of implantation failure and substandard IVF success rate (1-3). As such, preimplantation genetic 67 
screening (PGS) has been implemented into the clinics to identify euploid and aneuploid 68 
embryos prior to their transfer to the uterus. Thus, PGS has the capacity to prevent adverse IVF 69 
and pregnancy outcome, especially in women with advanced age (4-7). In assisted reproductive 70 
technology (ART) different biopsy methods are used to obtain the material for genetic analysis, 71 
including polar body biopsy of the oocyte, single blastomere biopsy of cleavage-stage embryos 72 
and trophectoderm (TE) biopsy of blastocysts. Polar body biopsy was shown to be the least 73 
efficient way of predicting embryo status, as it allows screening for maternal meiotic errors only, 74 
without taking into account paternally-derived and/or mitotic aneuploidies (8, 9). In contrast, 75 
blastomere biopsy directly evaluates embryonic genome, but it may not adequately represent the 76 
genomic status of the rest of the embryo due to the high-degree of post-zygotic chromosomal 77 
mosaicism at cleavage-stages of development that can be observed even in young fertile couples 78 
(10). Moreover, cleavage-stage embryos with abnormal cells may also develop into normal 79 
blastocysts (11). Hence, the genomic analysis has steadily shifted towards TE biopsy that is now 80 
widely adopted for PGS. In addition, TE biopsy is thought to be less harmful to the overall 81 
developmental capacity of the embryos, and currently chromosome analysis from the blastocyst 82 
stage may provide the most reliable representation of the embryonic genome due to the lower 83 
impact of mosaicism (12-15).  84 
Recently, the discovery of the amplifiable cell-free DNA in blastocoel fluid (BF) made it 85 
the object of attention by representing new source of DNA for genetic analysis (16). BF can be 86 
removed from the blastocyst prior to vitrification to protect the embryo from membrane damage 87 
arising from ice-crystal formation and improve embryo survival following cryopreservation (17, 88 
18). Although the volume of retrieved BF is usually relatively small, the study by Palini et al 89 
(16) successfully used the DNA from BF (BF-DNA) for whole-genome amplification (WGA), 90 
PCR and array comparative genomic hybridization (aCGH) for comprehensive chromosome 91 
analysis. Similarly, BF-DNA was also successfully subjected to next-generation sequencing 92 
(NGS) (19), supporting the idea that the aspiration of BF, a procedure termed blastocentesis (20), 93 
can become an alternative less invasive approach for blastocyst biopsy. However, given the 94 
remarkable genomic plasticity of early embryogenesis, the origin of genetic material in 95 
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blastocoel cavity awaits elucidation. In addition, the potential use of BF-DNA for PGS remains 96 
questionable, as few of the preliminary studies showed contradictive results regarding 97 
aneuploidy detection rates and karyotypic concordance between BF and different biopsied 98 
samples. So far, only one group was able to achieve high concordance rate when comparing 99 
genomic profiles of BF with TE cells, polar bodies and blastomeres (20, 21), while in other 100 
studies the discordance in karyotypes reached up to 50% between BF and TE biopsy or the rest 101 
of whole embryo (22-24). However, by using aCGH to compare the genomic consistency 102 
between BF-DNA and TE biopsies or the rest of the whole embryo, previously published studies 103 
were not able to investigate the occurrence of embryonic mosaicism, which is currently a 104 
prominent topic in PGS. Therefore, because of the inconsistent results and lack of data on 105 
blastocyst stage mosaicism, additional studies are warranted to investigate the potential use of 106 
BF-DNA for diagnostic purposes.  107 
Recently, NGS techniques were implemented in PGS, proving to be a more sensitive 108 
method for aneuploidy screening in embryos, because of the ability to reliably detect 109 
chromosomal mosaicism (25, 26). In the present study we utilized the most widely used 110 
VeriSeq™ PGS platforms for NGS-based comparative chromosome analysis of BF-DNA and 111 
TE and ICM cell populations. To our knowledge, this is the first pilot study to simultaneously 112 
evaluate molecular karyotypes of three different populations of cells derived from single 113 
blastocysts using high-resolution next generation sequencing. By analysing full and mosaic 114 
aberrations in different embryonic compartments, we aimed at unravelling to which extent the 115 
genomic profiles of BF, TE and ICM reflect each other at the blastocyst stage and to identify the 116 
source of DNA in blastocoel cavity. The data presented here provides novel insight into the 117 
feasibility of using BF-DNA in routine clinical practice. 118 
 119 
Materials and Methods 120 
Validation of mosaicism with mixing experiments 121 
First, we performed a proof-of-principle mixing experiment to evaluate the sensitivity of the 122 
Illumina VeriSeq™ NGS platform (Illumina, USA) in detecting mosaicism, as described recently 123 
(27, 28). Briefly, we obtained fibroblast cell lines with previously characterized karyotypes from 124 
the NIGMS Human Genetic Cell Repository at the Coriell Institute of Medical Research (USA). 125 
Aneuploid cell lines included trisomy 13 (47,XY,+13; GM02948), trisomy 18 (47,XY,+18; 126 
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GM01359) and trisomy 21 (47,XX,+21; GM04616). The cells were then cultured and passaged 127 
once as recommended by the supplier. Subsequently, individual cells from various cell cultures 128 
were isolated under dissecting microscope by EZ-Grip micropipette using 125 µm capillary 129 
(Research Instruments LTD, UK) and combined in different ratios, creating a mixture of six cells 130 
with different proportions of abnormal alleles of interest (0%, 17%, 33%, 50%, 66%, 83% and 131 
100%). Proof-of-principle experiments were performed in at least three replicates, each time by 132 
creating new cell mixtures. 133 
 134 
Embryo biopsy and sampling 135 
Embryo biopsy and sample collection was performed at the Tomsk regional perinatal center 136 
(Tomsk, Russia) and the Krasnoyarsk Center for Reproductive Medicine (Krasnoyarsk, Russia). 137 
The study was approved by the Bioethics Committee of the Biological Institute of the National 138 
Research Tomsk State University and all the patients have signed an informed consent. All 139 
micromanipulations were performed under a hood in a high-quality standard IVF laboratory  140 
 This study used 16 cryopreserved blastocysts, donated for research by patients who have 141 
undergone IVF treatment. Cryopreservation and thawing of blastocysts were done according to 142 
the manufacturer’s VT601-TOP/VT602-KIT protocol (Kitazato Corporation, Japan). Blastocyst 143 
morphology was evaluated using to the criteria set by Gardner and Schoolcraft, which is based 144 
on the assessment of blastocoele expansion and hatching status, size and compaction of the ICM, 145 
and number of TE cells and the presence of a cohesive layer (29). According to the study design, 146 
BF was first aspirated, and subsequently ICM and TE cells were isolated and collected for 147 
separate chromosome analysis. Blastocyst micropuncture and aspiration of BF was performed by 148 
previously described methods (20, 30). Briefly, the blastocysts were immobilized by a holding 149 
pipette, mounted on a micromanipulator, and BF from the cavity of expanded blastocysts was 150 
aspirated by an intracytoplasmic sperm injection (ICSI) micropipette (Origio, Denmark), which 151 
was inserted between the TE cells to minimize the possible cell damage. The use of ICSI 152 
micropipette also minimizes the risk of cross-contamination by intact TE or ICM cells. A single 153 
aspiration was performed, avoiding aspiration of any cellular material. A volume of ~1µl 154 
aspirated fluid was retrieved from each blastocyst.  The retrieved fluid was then expelled into the 155 
2.5 µl of 1x PBS, after which the end of the ICSI micropipette was broken into the tube to avoid 156 
any loss of the material. Subsequently, OCTAX Laser Shot™ microsurgical laser system (MTG, 157 
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Germany) or ZILOS-tk® (Hamilton Thorne, USA) were used to separate TE and ICM cells that 158 
were placed in separate tubes, containing 2.5 µl of 1x PBS. All biopsied materials were 159 
immediately whole-genome amplified and were stored in -20°C until further processing.  160 
 161 
Whole-genome amplification and next-generation sequencing 162 
Whole-genome amplification of all cell mixtures and biopsied samples was performed by 163 
commercial PCR-based PicoPLEX kit according to manufacturer’s protocol (Rubicon Genomics, 164 
USA). The quality of DNA amplification was controlled by 1% agarose gel electrophoresis and 165 
the amount of DNA was quantified by Qubit® dsDNA HS Assay kit (Thermo Fisher Scientific, 166 
USA). Subsequent processing of successfully amplified material and library preparations were 167 
done according to the manufacturer’s VeriSeq™ PGS kit protocol, after which the samples were 168 
sequenced with Illumina MiSeq® system. Data analysis and genome-wide profile visualization 169 
was performed by applying standard settings on Illumina BlueFuse Multi v4.3 Software with 170 
embedded aneuploidy calling algorithm. The detection sensitivity and the degree of mosaicism in 171 
mixture experiments and later in embryos were determined by BlueFuse Multi v4.3 numerical 172 
values.  173 
 174 
Statistical analysis 175 
Statistical calculations were performed using GraphPad Prism 6 software (GraphPad Software 176 
Inc., USA). The prevalence of chromosomal aberrations, including mosaic aneuploidies, in BF, 177 
TE and ICM was assessed with Chi-square test and the difference in the number of affected 178 
chromosomes between the embryo biopsies was considered to be statistically significant, when  179 
P-value was <0.002. To determine the potential value of BF-DNA use for aneuploidy screening 180 
two-tailed Fisher’s exact test was applied, when comparing the karyotype concordance of ICM 181 
between either BF or TE. 182 
 183 
Results 184 
We first performed mixing experiments to mimic possible mosaic aneuploidies observed in 185 
embryos. Internal validation of our mixing experiments revealed that NGS technique is able to 186 
distinguish mosaic losses and gains that are present in at least 20% of cells (Supplementary Fig. 187 
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S1), which is concordant to recent comprehensive validation studies on mosaicism detection 188 
using next-generation sequencing (27, 31).  189 
Next, a total of 16 cryopreserved embryos were biopsied with subsequent amplification 190 
of ICM-, TE- and BF-DNA for NGS analysis. After WGA, sufficient amount of DNA was 191 
detected in all of ICM and TE samples, but only in 14 out of 16 BF biopsies (87.5%). Following 192 
sequencing and initial quality control, BF chromosome profile could not be determined in four 193 
embryos. Out of those four embryos, two embryos also had an inconclusive result for either TE 194 
or ICM, so they were discarded from further investigation. Therefore, in 10 out of initial 16 195 
(62.5%) embryos chromosome copy number profiling was obtained for BF and compared to TE 196 
and ICM, while the comparison of TE and ICM was performed in 14 embryos out of 16 (87.5%).  197 
Based on the data of our mixing experiments and by using obtained numerical values of 198 
each embryo biopsy, we were able to determine the percentage of aneuploid cells present in BF, 199 
ICM, TE cells. However, because the detection of low-grade mosaicism within an embryo may 200 
be influenced in some degree to sampling error and technical artifacts (26, 32), we have 201 
classified our embryos according to the current Preimplantation Genetic Screening International 202 
Society (PGDIS) guidelines. Namely, embryos showing mosaicism of <20% were considered to 203 
be euploid and >80% were considered as aneuploid embryos with full chromosome losses or 204 
gains, while all the aneuploidies in the range of 20%-80% were classified as mosaic (Table 1). 205 
Importantly, when evaluating the data, overall noise ratio was also taken into account and mosaic 206 
aneuploidy calling was done with caution, as amplification artifacts can cause fluctuation in the 207 
genomic profiles that may be difficult to distinguish from low-level mosaicism, especially in the 208 
BF samples. We then compared the karyotypes of various biopsy types taken from the same 209 
embryo and classified our results as was performed previously: (1) full concordance was 210 
reported, if all biopsied samples were euploid or if the same chromosomes were affected in 211 
biopsied samples (including mosaic and/or reciprocal losses and gains); (2) partial concordance 212 
was reported, when at least one chromosome corresponded in both biopsies under comparison, 213 
but the overall genomic profile did not completely match; and (3) discordance was reported, 214 
when none of the affected chromosomes in one biopsy corresponded to other biopsies (21). 215 
Based on the results of our study, a full chromosome concordance between the three cellular 216 
populations was observed only in four embryos, of which three were uniformly euploid and one 217 
had a reciprocal mosaic aneuploidy (e.g Embryo 1 in Table 1; Fig. 1). In general, reciprocal 218 
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aneuploidies in BF were observed in three embryos, indicating a post-zygotic nature of 219 
chromosome abnormalities due to chromosome non-disjunction during mitosis. We have also 220 
detected a potentially polyploid partially concordant embryo with multiple reciprocal losses and 221 
gains in all three embryo compartments (Embryo 3 in Table 1; Fig. 2A). Such genomic profile 222 
could be a consequence of chromosome missegregations during the first post-zygotic cleavages 223 
that accumulated throughout the preimplantation development, resulting in an unviable embryo. 224 
At the same time, we have observed another chaotic profile in the BF-DNA only, while the 225 
corresponding TE and ICM had a euploid karyotype (Embryo 4 in Table 1; Fig. 2B). Similarly to 226 
this, also embryo 7 showed multiple aneuploidy profile in the BF, while both ICM and TE were 227 
normal. Owing to such differences in karyotypes, it comes as no surprise that in total the overall 228 
number of affected pairs of chromosomes (22 pairs of autosomes and one pair of sex 229 
chromosomes), including the potentially polyploid biopsies with whole affected genome, was 230 
higher in ten BF samples (79/230), compared to corresponding TE (34/230) or ICM biopsies 231 
(26/230) (both P<0.0001), while no such difference was observed between the available 14 ICM 232 
(27/322) and TE biopsies (35/322) (P=ns). As such, BF karyotype was discordant from ICM in 233 
30.0% (3/10) of the cases and from TE in 20.0% (2/10) of the cases. Thus, BF-DNA karyotype 234 
reached full concordance between either ICM or TE in 40.0% (4/10) of the embryos (Table 2). In 235 
contrast, full concordance between ICM and TE was observed in 85.7% (12/14) of the embryos, 236 
making TE more representative of embryonic chromosomal status than BF (P<0.03). Therefore, 237 
our data suggests that using BF-DNA as a single source of DNA for PGS can potentially lead to 238 
an increased rate of false positive findings. This means that a viable embryo with euploid 239 
genome can be discarded based only on the aberrant BF-DNA karyotype, leading to suboptimal 240 
IVF success rate.  241 
 242 
Discussion 243 
Blastocyst culture has become a milestone in ART and is now widely used for selection of viable 244 
embryos for transfer. The design of our study enabled us to simultaneously compare for the first 245 
time the molecular karyotypes of cells from three major blastocyst components: inner cell mass, 246 
trophectoderm and blastocoel fluid, also taking into account the mosaic nature of embryos at this 247 
late stage of preimplantation development. In our cohort of embryos, the BF-DNA karyotype 248 
was fully concordant to ICM or TE cells in only 40.0% of cases, compared to 85.7% between 249 
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ICM and TE. This result is similar to previously published report, demonstrating 48% 250 
concordance rate between BF and the rest of the analyzed ICM and TE cells (24), although it 251 
drastically contrasts with the high concordance rates achieved by another group (20, 21). Such 252 
contradictory outcome may be explained by different types of material analyzed and in our case 253 
also by a different technological approach. The genomic profile of blastocysts may include 254 
mosaicism that can be missed by aCGH, which is able to detect only high-degree mosaicism, 255 
when >50% of cells are aneuploid (33). By using NGS method with improved resolution and 256 
sensitivity, we were also able to determine embryos carrying 20-40% of abnormal cells. 257 
Moreover, the reciprocal nature of some of the chromosome abnormalities indicate that what we 258 
observed were not technical artifacts, but rather true biological events that happened during post-259 
zygotic cleavages. In addition, we have detected two embryos with the same full chromosome 260 
aberrations in all three embryonic biopsies, indicating the meiotic nature of these aneuploidies 261 
(e.g. Embryo 2 and Embryo 5).  262 
The presence of embryonic DNA in BF suggest that potential mechanisms might exist by 263 
which the genetic material is released into the blastocoel cavity, like cell lysis, apoptosis and 264 
elimination of cellular debris (34). Interestingly, the intact ICM karyotype in the presence of 265 
aneuploidy in BF-DNA in some of the embryos also seems to support the idea that aneuploid 266 
cells are progressively depleted from the developing embryo through apoptosis, ensuring the 267 
genomic integrity of the future fetus (35). This phenomenon might also be one of the biological 268 
explanations of the high concordance rate previously observed between BF-DNA and 269 
blastomeres (21), as aberrant cells may be marginalized into the blastocoel cavity at later stages 270 
of development. Such mechanism may also likely explain why transfer of mosaic embryos can 271 
lead to live birth (36), although the impact of embryonic mosaicism on pregnancy outcome is 272 
currently under intense investigation (25, 27). Therefore, the biology behind data interpretation, 273 
especially the one derived from BF-DNA, must be adequately elucidated to provide proper 274 
patient counselling in everyday clinical practice. 275 
 In addition to biological challenges, technical limitations can also restrict the use of BF as 276 
a source of DNA for PGS using NGS, as BF can contain a variable amount of cell-free DNA, 277 
which may vary in size (19). Moreover, BF-DNA can become fragmented or degraded, which 278 
can affect whole-genome amplification rates. In addition, 10the limited quantity of available 279 
starting material may be prone to uneven amplification and allele drop-out (37). In addition, 280 
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library preparation methods and technical artifacts can result in an altered representation of the 281 
genome that will reduce the reliability of chromosome analysis (31). Because VeriSeqTM protocol 282 
is not suitable for handling DNA fragments less than 300bp, smaller fragments present in the 283 
cell-free DNA may be lost upon library preparation for sequencing, leading to genomic 284 
underrepresentation and overall higher noise ratio of the sequenced data. In contrast, the 285 
amplification rate and quality of the data were much higher in TE and ICM cells, and our results 286 
showed that TE is quite representative of ICM. In addition, no evidence of preferential allocation 287 
of aneuploid cells to trophectoderm was observed.  288 
 Based on our data, the genomic profiles of TE and ICM showed either generally lower 289 
level of mosaicism or the absence of aneuploidy at all, if compared to BF-DNA profiles. Hence, 290 
from the clinical and diagnostic point of view the use of insensitive to mosaicism aCGH platform 291 
(that detects only >50% mosaicism) might seem like a more suitable approach for the analysis of 292 
BF-DNA that could potentially increase the karyotypic concordance rate between different 293 
embryo compartments, because the biologically irrelevant low-grade mosaicism in BF would not 294 
be detected. On the other hand, embryos with normal TE and ICM karyotype also showed high-295 
grade mosaic aneuploidies in BF that would likely be interpreted as false positive finding using 296 
aCGH, thus leading to misdiagnosis.  Because such discordance was also evident in previous 297 
studies using aCGH (22-24), together our results suggest that at this point chromosome analysis 298 
of TE biopsy remains a more optimal and effective way of predicting the karyotype of the 299 
blastocyst. However, a more sophisticated bioinformatical approaches are still warranted to 300 
overcome the challenges in mosaic aneuploidy calling and help refine the criteria for embryo 301 
selection for transfer without compromising the treatment success rate by excluding mosaic 302 
embryos capable of resulting in viable pregnancies. 303 
The limiting aspect of our pilot study was the number of embryos analyzed. In addition, 304 
when looking at TE cells, we sequenced the whole trophectoderm cell population. This is 305 
opposite to TE biopsy, when only a small number of cells are analyzed that may not necessarily 306 
represent the karyotype of the rest of the embryo. In our case, euploid cells could have 307 
potentially normalized the genomic profile of TE samples, making low-level mosaicism 308 
undetectable. Similarly, a mixture of cells with monosomy and trisomy of the same chromosome 309 
(reciprocal aneuploidies) can also result in genomic normalization below the level of mosaicism 310 
detection, leading to a false diagnosis of disomy. Finally, we also acknowledge that the 311 
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aspiration of BF was performed after embryo thawing, which can potentially affect the quality of 312 
DNA and subsequent results. Another important consideration is whether any contaminating 313 
genetic material from culture medium or extracellular vesicles can arise during BF isolation. 314 
Perhaps, advanced genome-wide haplotyping technologies can shed some light on the true origin 315 
of BF-DNA in blastocoel cavity.  316 
 In conclusion, we have corroborated that BF-DNA can be amplified and applied for next-317 
generation sequencing. However, based on the observations of this study, the results obtained 318 
from BF-DNA do not seem to be comparable to those obtained via standard TE biopsies, and 319 
BF-DNA does not adequately represent the rest of the embryo, making it diagnostically 320 
unacceptable, at least using current methods and protocols. In addition, although the impact of 321 
BF sampling seems less invasive, functional studies on the effect of BF biopsy on embryo 322 
viability may be warranted, as blastocoel may contain proteins crucial for embryonic 323 
development (38). Nonetheless, the potential use of blastocoel sampling cannot be ruled out in 324 
the future, although the improvement of current sample handling protocols and development of 325 
novel bioinformatical tools are required. Therefore, all the limitations must be carefully 326 
evaluated before BF-DNA can be used as a single alternative approach for embryonic aneuploidy 327 
screening. 328 
 329 
 330 
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Figures and Figure Legends 449 
 450 
 451 
Figure 1. A fully concordant embryo with reciprocal mosaic aneuploidy  452 
Example of an embryo (Embryo 1; Table 1) with a 70% mosaic loss of chromosome 9 in the 453 
blastocoel fluid (BF) and a reciprocal gain in the trophectoderm cells (TE; 50%) and inner cell 454 
mass (ICM; 20%). The decreased rate of mosaicism in the ICM suggests that aberrant cells may 455 
be marginalized from the ICM lineage.  456 
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 457 
Figure 2. Examples of embryos with chaotic chromosome profiles  458 
(A) Embryo 3 (Table 1) with numerous losses and gains observed in all three blastocysts 459 
compartments. Deviations in the numerical values of autosomes and sex chromosomes suggest a 460 
potential polyploid karyotype. This embryo was classified as partially concordant. (B) 461 
Chromosome plots of Embryo 4 (Table 1) with a discordant karyotype between the blastocoel 462 
fluid (BF) and trophectoderm (TE) or inner cell mass (ICM). 463 
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 464 
Supplementary Figure S1. NGS proof-of-principle mixing experiments 465 
Cells with known aneuploid karyotype were mixed at different proportions with normal diploid 466 
cells to mimic mosaicism in embryos. Mixing experiments were done in at least three replicates 467 
and copy number (CN) value was evaluated. Each shape and error bar indicate mean and 468 
standard deviation of all independent measurements. 469 
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Table 1. Molecular karyotypes of the blastocoel fluid, trophectoderm and inner cell mass  470 
Embryo # Patient 
Age 
Embryo 
Morphology 
Blastocoel fluid 
(% of mosaicism)  
Trophectoderm 
(% of mosaicism) 
Inner Cell Mass 
(% of mosaicism) 
1 39 3BB 46,XX 
Mosaic -9 (70%) 
46,XX 
Mosaic +9 (50%) 
46,XX 
Mosaic +9 (20%)  
2 39 3-4BB 45,XY, -13 
Mosaic +1 (60%) 
Mosaic -16 (30%) 
Mosaic -21 (40%) 
45,XY, -13 45,XY, -13 
3 39 3-4BB Chaotic, likely polyploid Chaotic, likely polyploid Chaotic, likely polyploid 
4 33 3-4AB Chaotic, likely polyploid 46,XY 46,XY 
5 33 4BB 45,XY, -7 
Mosaic -1 (50%) 
Mosaic +8 (60%) 
Mosaic +11 (50%) 
Mosaic +18 (40%) 
Mosaic +20 (40%) 
Mosaic +21 (50%) 
45,XY, -7 
 
45,XY, -7 
 
6 37 4-5BB 44, XX,-9,-9 
Mosaic -3 (60%) 
Mosaic -10 (80%) 
Mosaic -12 (70%) 
Mosaic -13 (80%) 
Mosaic +14 (50%) 
Mosaic -15 (70%) 
Mosaic +16 (50%) 
Mosaic +17 (50%) 
Mosaic +19 (50%) 
Mosaic +20 (50%) 
Mosaic -22 (70%) 
46,XX 
Mosaic +3 (20%) 
Mosaic +9 (50%) 
Mosaic +10 (30%) 
Mosaic +12 (20%) 
Mosaic +13 (30%) 
Mosaic +15 (20%) 
Mosaic -20 (30%) 
Mosaic +22 (30%) 
46,XX 
7 37 4-5AA 47,XY,+11 
Mosaic +2 (80%) 
Mosaic -9 (30%) 
46,XY 46,XY 
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Mosaic -10 (30%) 
Mosaic -12 (30%) 
Mosaic -13 (40%) 
Mosaic +19 (50%) 
Mosaic -21 (50%) 
Mosaic –X (60%) 
8 32 5BB ND 46,XY 46,XY 
9 23 4BB 46,XX 46,XX 46,XX 
10 23 5BB 46,XX 46,XX 46,XX 
11 32 4BB 46,XX 46,XX 46,XX 
12 32 4BB ND 46,XX 46,XX 
13 32 4BB ND 46,XX 46,XX 
14 42 3BC ND 46,XY 
Mosaic -17 (80%) 
46,XY 
Mosaic -17 (70%) 
Note: The chaotic likely polyploid profiles of embryos 3 and 4 are depicted in Fig. 2.; ND, chromosome profile not determined471 
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Table 2. Concordance levels between the blastocoel fluid (BF), trophectoderm 
(TE) and inner cell mass (ICM) 
 
Concordant Partially concordant Discordant 
BF vs ICM 40.0% (4/10) 30.0% (3/10) 30.0% (3/10) 
BF vs TE 40.0% (4/10) 40.0% (4/10) 20.0% (2/10) 
TE vs ICM 85.7% (12/14) 7.1% (1/14) 7.1% (1/14) 
 
 
